Payment overview · 2025
General Payments
$224.30
8 reported records · 4 companies
Healthcare provider profile · identity verified
Dlynn Danielle Rogers, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · HAWKINSVILLE, GA · NPI 1568045292
Verified facts
What the public records show
CMS Open Payments records show Dlynn Danielle Rogers, APRN received $224.30 in general payments during 2025 across 8 reported records.
Corcept Therapeutics accounted for 70.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Korlym.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Farxiga by this doctor in 2024.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Korlym by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $158.67 | 70.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.02 | 16.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.50 | 6.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.11 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $224.30 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $158.67 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 75 | exact normalized | Medicare Part D |
| Korlym korlym |
2025 | Korlym | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
75 | 25 |
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 100 | 35 |
| Mounjaro | Tirzepatide | 87 | 17 |
| Ezetimibe | Ezetimibe | 82 | 30 |
| Farxiga | Dapagliflozin Propanediol | 75 | 25 |
| Potassium Chloride | Potassium Chloride | 75 | 32 |
| Gabapentin | Gabapentin | 74 | 27 |
| Tramadol Hcl | Tramadol Hcl | 74 | 22 |
| Trazodone Hcl | Trazodone Hcl | 73 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 63 | 31 |
| Losartan Potassium | Losartan Potassium | 51 | 21 |
| Montelukast Sodium | Montelukast Sodium | 50 | 17 |
| Atorvastatin Calcium | Atorvastatin Calcium | 49 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 16 |
| Fluconazole | Fluconazole | 43 | 30 |
| Famotidine | Famotidine | 39 | 14 |
| Linzess | Linaclotide | 38 | suppressed |
| Ozempic | Semaglutide | 38 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 38 | 16 |
| Simvastatin | Simvastatin | 38 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 13 |
| Chlorthalidone | Chlorthalidone | 35 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 14 |
| Lisinopril | Lisinopril | 35 | 15 |
| Omeprazole | Omeprazole | 34 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 26 |
| Repatha Sureclick | Evolocumab | 33 | suppressed |
| Prednisone | Prednisone | 32 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Furosemide | Furosemide | 26 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 16 |
| Alprazolam | Alprazolam | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | 14 |
| Spironolactone | Spironolactone | 21 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Nexletol | Bempedoic Acid | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 14 |
| Celecoxib | Celecoxib | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | 11 |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Metformin Hcl | Metformin Hcl | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 13 |
| Korlym | Mifepristone | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $224.30 · 8 records | Corcept Therapeutics | FARXIGA, Korlym, OTEZLA, REPATHA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error